United Therapeutics Corporation (NASDAQ:UTHR) will hold its 3Q20 earnings conference call with the financial community on 28th October 2020 at 9:00 AM Eastern Time.
The conference call will be webcast live on Internet at www.unither.com
Earnings Expectation
United Therapeutics Corporation drug manufacturer, is reporting third quarter earnings results on Wednesday 28th October 2020, before market open.
The consensus estimates from Thomson Reuters are income of $ 2.78 per share from $ 356.95 million in revenue. For the full year, analysts predict revenues of $ 1424.51 million, while looking forward to income of $ 11.39 per share.
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The companys commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma. It also engages in developing esuberaprost, RemoPro, Treprostinil Technosphere, Trevyent, ralinepag, and Aurora-GT to treat PAH; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, biomechanical lungs, and ex-vivo lung perfusion, as well as the development of medicine for other diseases.
